Grufity logoGrufity logo

ZLAB

34.00USD+0.27(+0.80%)Market Closed

Zai Lab Ltd

Market Summary

USD34.00+0.27Market Closed
0.80%

ZLAB Alerts

ZLAB Stock Price

RSI Chart

Valuation

Market Cap

22.8B

Price/Earnings

-43.07

Price/Sales

124.96

Price/Cashflow

-51.05

MarketCap/EBT

-43.16

Price/Sales

Profitability

Operating Margin

63.27%

EBT Margin

-289.55%

Return on Equity

-43.6%

Return on Assets

-37.25%

Fundamentals

Revenue

Revenue (TTM)

196.6M

Revenue Y/Y

33.49%

Revenue Q/Q

19.44%

Earnings

Earnings (TTM)

-593.3M

Earnings Y/Y

-67.19%

Earnings Q/Q

-16.86%

Price Action

52 Week Range

20.9873.85
(Low)(High)

Last 7 days

0.9%

Last 30 days

9.9%

Last 90 days

-26.3%

Trailing 12 Months

-46.9%

Financial Health

Current Ratio

7.91

Investor Care

Shares Dilution (1Y)

907.34%

Diluted EPS (TTM)

-2.62

Financials for Zai Lab

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue7.9%197182171144115
  S&GA Expenses3.0%257249240219190
  R&D Expenses12.8%392347423573464
Earnings Before Taxes-12.3%-592.61-527.49-552.48-703.41-569.32
Net Income-12.3%-593.34-528.56-553.96-704.47-569.19
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.5%1,2991,4191,5011,6101,728
  Current Assets-9.4%1,2101,3361,3931,5011,619
    Cash Equivalents64.4%1,1196818479641,398
  Inventory24.9%2923201912
  Net PPE8.9%5146454337
Liabilities-6.8%193207193230140
  Current Liabilities-7.9%156169155193112
Shareholder's Equity-8.8%1,1061,2121,3081,3801,588
  Retained Earnings-9.8%-1,799.59-1,638.40-1,500.47-1,418.07-1,206.25
  Additional Paid-In Capital0.7%2,8772,8572,8392,8262,813
Accumulated Depreciation6.2%2019181615
Shares Outstanding0.1%96095895795595
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations7.8%-411.34-445.91-466.86-549.23-440.57
  Share Based Compensation17.2%5850464133
Cashflow From Investing122.6%143-631.74-522.19250731
Cashflow From Financing39.5%-1.81-2.99821820928

Risks

What is the probability of a big loss on ZLAB?

86.9%


Probability that Zai Lab stock will be more than 20% underwater in next one year

57.7%


Probability that Zai Lab stock will be more than 30% underwater in next one year.

35%


Probability that Zai Lab stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZLAB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zai Lab was unfortunately bought at previous high price.

Returns

Cumulative Returns on ZLAB

5.9%


5-Year Cumulative Returns

-6.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ZLAB?

FIve years rolling returns for Zai Lab.

Which funds bought or sold ZLAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-89,000
921,000
-%
2022-11-18
National Pension Service
ADDED
2.36
22,000
644,000
-%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
508,000
508,000
-%
2022-11-15
STATE STREET CORP
ADDED
4.86
1,727,000
52,463,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
NOMURA HOLDINGS INC
SOLD OFF
-100
-454,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-20.08
-1,007,590
3,748,080
0.01%
2022-11-15
Kingsview Wealth Management, LLC
ADDED
2.81
3,000
238,000
0.01%
2022-11-14
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC
REDUCED
-1.52
-33,000
1,109,000
-%
2022-11-14
ETF MANAGERS GROUP, LLC
REDUCED
-31.2
-342,000
730,000
0.02%

1–10 of 46

Latest Funds Activity

Are funds buying ZLAB calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ZLAB

Zai Lab News

Marketscreener.com

Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).38 hours ago

ZLAB Fair Value

Recent SEC filings of Zai Lab

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Oct 28, 2022
S-8
Employee Benefits Plan
Oct 28, 2022
8-K
Current Report
Sep 27, 2022
8-K
Current Report

Latest Insider Trading transactions for ZLAB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
Reinhart Harald
SOLD
-74,163
40.0016
-1,854
See Remarks
2022-11-15
Reinhart Harald
ACQUIRED
5,562
3
1,854
See Remarks
2022-08-17
Edmondson Frazor Titus III
SOLD (Taxes)
-51,397.1
43.52
-1,181
Chief Legal Officer
2022-08-17
Edmondson Frazor Titus III
ACQUIRED
211,072
43.52
4,850
Chief Legal Officer
2022-04-01
Reinhart Harald
ACQUIRED
-
-
1,010
See Remarks
2022-04-01
Cho William Ki Chul
ACQUIRED
-
-
920
Chief Financial Officer
2022-04-01
Sandler Alan B.
ACQUIRED
-
-
1,060
Head of Global Dev., Oncology
2022-04-01
Edmondson Frazor Titus III
SOLD (Taxes)
-9,230.41
45.47
-203
Chief Legal Officer
2022-04-01
Du Ying
ACQUIRED
-
-
3,400
Chairwoman & CEO
2022-04-01
Reinhart Harald
SOLD FOR TAXES
-11,185.6
45.47
-246
See Remarks

1–10 of 50

ZLAB Income Statement

2022-09-30
Unaudited condensed consolidated statements of operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Product revenue, net$ 56,963,000$ 43,103,000$ 150,633,000$ 100,141,000
Collaboration revenue577,00001,806,0000
Total revenues57,540,00043,103,000152,439,000100,141,000
Expenses:    
Cost of sales(20,044,000)(12,162,000)(53,094,000)(30,535,000)
Research and development(99,524,000)(55,144,000)(219,462,000)(401,220,000)
Selling, general, and administrative(66,555,000)(59,002,000)(186,947,000)(149,254,000)
Loss from operations(128,583,000)(83,205,000)(307,064,000)(480,868,000)
Interest income3,872,000713,0005,235,0001,171,000
Other income (expenses), net(36,479,000)(13,580,000)(79,467,000)(12,401,000)
Loss before income tax and share of loss from equity method investment(161,190,000)(96,072,000)(381,296,000)(492,098,000)
Income tax expense0000
Share of loss from equity method investment0(340,000)(221,000)(548,000)
Net loss(161,190,000)(96,412,000)(381,517,000)(492,646,000)
Net loss attributable to ordinary shareholders - basic(161,190,000)(96,412,000)(381,517,000)(492,646,000)
Net loss attributable to ordinary shareholders - diluted$ (161,190,000)$ (96,412,000)$ (381,517,000)$ (492,646,000)
Loss per share/ADS - basic (in dollars per share)$ (0.17)$ (0.10)$ (0.40)$ (0.53)
Loss per share/ADS - diluted (in dollars per share)$ (0.17)$ (0.10)$ (0.40)$ (0.53)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)959,085,960950,354,320957,439,910921,748,380
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)959,085,960950,354,320957,439,910921,748,380
American Depositary Shares    
Expenses:    
Loss per share/ADS - basic (in dollars per share)$ (1.68)$ (1.01)$ (3.98)$ (5.34)
Loss per share/ADS - diluted (in dollars per share)$ (1.68)$ (1.01)$ (3.98)$ (5.34)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)95,908,59695,035,43295,743,99192,174,838
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)95,908,59695,035,43295,743,99192,174,838

ZLAB Balance Sheet

2022-09-30
Unaudited condensed consolidated balance sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,119,476$ 964,100
Short-term investments0445,000
Accounts receivable (net of allowance for credit loss of $8 and $11 as of September 30, 2022 and December 31, 2021, respectively)27,73647,474
Notes receivable10,2517,335
Inventories, net29,13118,951
Value added tax recoverable - current1,0800
Prepayments and other current assets22,15718,021
Total current assets1,209,8311,500,881
Restricted cash, non-current803803
Long term investments (including the fair value measured investment of $3,316 and $15,383 as of September 30, 2022 and December 31, 2021, respectively)3,31615,605
Prepayments for equipment4,068989
Property and equipment, net50,52843,102
Operating lease right-of-use assets20,26914,189
Land use rights, net6,8247,811
Intangible assets, net1,5401,848
Long-term deposits1,329870
Value added tax recoverable623,858
Total assets1,298,5141,609,956
Current liabilities:  
Accounts payable90,112126,163
Current operating lease liabilities6,9805,927
Other current liabilities58,45660,811
Total current liabilities155,548192,901
Deferred income23,20527,486
Non-current operating lease liabilities13,8929,613
Total liabilities192,645230,000
Commitments and contingencies (Note 14)
Shareholders’ equity  
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 961,829,720 and 955,363,980 shares issued as of September 30, 2022 and December 31, 2021, respectively; 959,724,940 and 954,981,050 shares outstanding as of September 30, 2022 and December 31, 2021, respectively)66
Additional paid-in capital2,877,3612,825,948
Accumulated deficit(1,799,591)(1,418,074)
Accumulated other comprehensive income (loss)39,549(23,645)
Treasury Stock (at cost, 2,104,780 and 382,930 shares as of September 30, 2022 and December 31, 2021, respectively)(11,456)(4,279)
Total shareholders’ equity1,105,8691,379,956
Total liabilities and shareholders’ equity$ 1,298,514$ 1,609,956